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Cyclin D1 (CCND1) plays a key role in cell cycle control, particularly in the transition from G1 to S phase, which is regulated by cyclin-
dependent kinases. A common adenine to guanine polymorphism (A870G) in the CCND1 gene has been associated with a longer-life
protein and an increased risk of colorectal cancer and adenoma in some studies. Among subjects with hereditary nonpolyposis
colorectal cancer, the A870G polymorphism has also been associated with a younger age of onset of colorectal cancer. We analysed
181 colorectal cancer cases and 475 matched controls and 524 adenoma cases and 517 matched controls within women in the
Nurses’ Health Study (NHS) cohort, 171 colorectal cancer cases and 347 matched controls and 372 adenoma cases and 712
matched controls nested within men in the Health Professionals’ Follow-Up Study (HPFS) cohort, and 258 colorectal cancer cases
and 415 matched controls within men in the Physicians’ Health Study (PHS) cohort to assess the risk associated with the CCND1
A870G genotype. Moreover, we assessed whether CCND1 genotype modified the effect of a sporadic (nonsyndromic) family history
of colorectal cancer as well as the effect of other dietary and lifestyle risk factors for colorectal cancer and adenoma. In all cohorts
combined, the CCND1 polymorphism did not show statistically significant associations to risk of colorectal cancer (odds ratio (OR) for
A allele carriers, 1.04; 95% confidence interval (95% CI), 0.82–1.32) or adenoma (OR, 0.96; 95% CI, 0.79–1.18). The CCND1 A870G
genotype was associated with a modest, although nonsignificantly elevated risk of colorectal cancer (OR, 1.59; 95% CI, 0.98–2.57) in
women. In contrast, the polymorphism was not associated with increased risk of adenoma in either men or women. Among
participants with the A870G genotype, a family history of colorectal cancer conferred a substantially greater risk of colorectal cancer
in the women (P for interaction¼0.06) and adenoma in the men (P for interaction¼0.02). Current postmenopausal hormone
(PMH) use was associated with a significant reduction in the risk of colorectal cancer and adenoma among women with the A870G
genotype, whereas there was no effect of PMH use among those with the GG genotype. The CCND1 polymorphism appeared to
confer a modest elevation in the risk of colorectal cancer among women. Moreover, the A870G genotype may enhance the
protective effect of postmenopausal oestrogen use on the development of colorectal neoplasia.
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Cyclin D1 (CCND1) is a protein that plays a key role in cell cycle
control, particularly in the transition from G1 to S phase, which is
regulated by cyclin-dependent kinases (Sherr, 1996). The over-
expression of the CCND1 gene occurs in more than one-third of all
colorectal cancers (Arber et al, 1996) and adenoma (Weinstein
et al, 1997), and expression of an antisense CCND1 cDNA
suppresses the growth of colon cancer cells in animal models
(Arber et al, 1997).
Cyclin D1 mRNA is alternatively spliced between exons 4 and 5
to generate two transcripts, which may be concurrently transcribed
in various human tissues (Betticher et al, 1995). A common G to A
polymorphism at codon 242 on exon 4 in the CCND1 gene
has been shown to modulate splicing of the CCND1 transcript
(Betticher et al, 1995). The dominant A allele preferentially
generates the truncated transcript (Weinstein et al, 1997; Sawa
et al, 1998), which encodes a cyclin D1 protein with a longer half-
life. This accumulation of cyclin D1 in the cell may promote cell
proliferation and the subsequent development of colorectal cancer.
Previous studies have had inconsistent results for an association
of the CCND1 A870G polymorphism with bladder cancer
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s(Cortessis et al, 2003; Wang et al, 2003b; Berman et al, 2004; Ito
et al, 2004), endometrial cancer (Kang et al, 2005), breast cancer
(Grieu et al, 2003; Krippl et al, 2003; Shu et al, 2005), head and
neck cancer (Zheng et al, 2001), gastric and oesophageal cancer
(Wang et al, 2003c; Zhang et al, 2003a), hepatocellular carcinoma
(Zhang et al, 2003b), lung cancer (Qiuling et al, 2003), and prostate
cancer (Koike et al, 2003; Wang et al, 2003a). The strongest
evidence, to date, has linked the CCND1 A870G polymorphism
with an increased risk of colorectal cancer and adenoma in many
(Kong et al, 2000, 2001; Bala and Peltomaki, 2001; Porter et al,
2002) though not all studies (McKay et al, 2000). Moreover, the
CCND1 A870G genotype (Kong et al, 2000) or the presence of
the variant truncated CCND1 transcript (preferentially encoded by
the A870G genotype) (Bala and Peltomaki, 2001) was associated
with a younger age of cancer onset in subjects with hereditary
nonpolyposis colorectal cancer (HNPCC). Nonetheless, few studies
have examined the influence of the genotype among subjects with
a common family history of colorectal cancer (e.g., one or two
affected first-degree relatives), and few have assessed potential
interactions between dietary and other environmental risk factors
and CCND1 genotype.
We therefore examined the influence of the CCND1 A870G
polymorphism on the risk of colorectal cancer and adenoma in
three large prospective cohort studies, the Nurses’ Health Study
(NHS), the Health Professionals’ Follow-Up Study (HPFS), and the
Physicians’ Health Study (PHS). Using banked blood specimens
and regularly updated data on dietary and lifestyle risk factors, we
assessed whether the influence of these environmental factors was
modified by the CCND1 polymorphism.
MATERIALS AND METHODS
Study subjects
The NHS is an ongoing prospective study of 121700 US female
registered nurses. Details of the design and follow-up of this cohort
have been described previously (Chen et al, 1998). Briefly, at
enrollment in 1976, the participants, who were 30–55 years old,
completed a mailed questionnaire providing information on risk
factors for cancer and cardiovascular disease. Biennially, updated
exposure and disease information is collected by mail, including
reports of endoscopy and polyp diagnosis. Self-reported diagnoses
of colorectal cancer and adenoma are confirmed through histo-
pathological reports reviewed by a study investigator. From 1989
to 1990, blood samples were collected from 32826 of the NHS
participants. For the analysis of cancers, we confirmed 197 cases of
colorectal cancer diagnosed after blood collection through 1 June
2000 among eligible women. In all, 590 women who were free from
cancer at the time of case assessment were selected as controls for
the cancer cases and matched on year of birth and month of blood
draw.
Eligible women for the selection of either an adenoma case or
adenoma control were those women who reported a sigmoido-
scopy and/or colonoscopy after providing a blood sample and
were free from inflammatory bowel disease, a polyposis syndrome,
or diagnosed cancer (except nonmelanoma skin cancer). As
in previous studies (Chan et al, 2004), to avoid detection bias,
we defined adenoma cases as one or more pathology-verified
adenoma less than 60cm from the anus. In both the NHS and
HPFS, although we asked participants if they underwent sigmoido-
scopy or colonoscopy, we did not ask them to specify the type of
procedure. Thus, during the study period, for the analysis of
adenoma in both cohorts, we assumed that a substantial portion
of all procedures were sigmoidoscopies, which encompass only
examination of the distal colon and rectum. One control was
matched to each case according to year of birth, month of blood
draw, fasting status, time period of endoscopy (within 2 years),
and routine screening, gastrointestinal symptoms, or family
history of colorectal cancer as indication(s) for endoscopy. A total
of 557 cases and 557 matched controls were identified. Sub-
sequently, one colon polyp case was identified as hyperplastic
and removed from the final analysis, which included 556 cases and
557 controls.
The HPFS began in 1986 when 51529 US male dentists,
optometrists, osteopaths, podiatrists, pharmacists, and veterinar-
ians, aged 40–75 years, responded to a mailed questionnaire
(Giovannucci et al, 1993). These men provided baseline informa-
tion on age, marital status, height and weight, ancestry, medica-
tions, smoking history, medical history, physical activity, and diet.
Exposure and medical history information are updated every 2
years. When a participant reported a diagnosis of colorectal
adenoma on the follow-up questionnaires, we asked for permission
to acquire the relevant medical records. All cases in this analysis
were confirmed through histopathologic reports reviewed by a
study investigator. Blood samples were collected between 1993 and
1994 from 18025 participants, among whom 367 had been
diagnosed with adenomatous polyps between 1986 and 1994 and
were confirmed by medical records. To be eligible for selection as a
case or control, a person must have completed a valid dietary
questionnaire in 1986, supplied a blood sample, and have
undergone sigmoidoscopy or colonoscopy after 1986, and not
have had a cancer diagnosis, excluding nonmelanoma skin cancer,
before the date of endoscopy. A total of 736 men who were free
from diagnosed polyps at the time of case assessment were selected
as controls and matched to each case on year of birth, whether they
had had a previous endoscopy, and year of endoscopy. Subse-
quently, nine controls were identified as cases, so the final set
included 376 cases and 725 controls. For the analysis of cancers, we
confirmed 182 cases of colorectal cancer diagnosed after blood
collection through 1 June 2002 among eligible men. In total, 364
men who were free from cancer at the time of case assessment were
selected as controls for the cancer cases and matched on year of
birth and month of blood draw.
The PHS is a randomised, double-blind trial of aspirin and b-
carotene among 22071 predominantly Caucasian-American male
physicians, 40–84 years of age in 1982. Blood samples were
collected at baseline, in 1982, from 14916 (68%) of the randomised
physicians. The men were subsequently followed for incident
cancer through annual mailed questionnaires. By the year 2000,
272 cases of colorectal cancer were identified and confirmed using
medical records. Men who were free from diagnosed cancer at the
time of cancer ascertainment (n¼456) were selected as controls,
and were matched on age (71 year; up to 75 years for older men)
and on smoking history at baseline (current, former, and never-
smokers).
Sample collection
In both the NHS and HPFS, venous blood samples were separated
into plasma, buffy coat and red blood cells and stored in liquid
nitrogen. Genomic DNA was extracted from whole blood samples
(PHS) or from 50ml buffy coat diluted with 150ml of phosphate-
buffered saline and using the QIAmp (Qiagen Inc., Chatsworth,
CA, USA) 96-spin blood protocol according to the manufacturer’s
instructions. Genomic DNA concentrations were calculated in
96-well format using PicoGreen technology (Molecular Probes,
Eugene, OR, USA).
Cyclin D genotype
Genotyping of CCND1 was carried out using the TaqMan allelic
discrimination system (Applied Biosystems, Foster City, CA, USA).
TaqMan primers and probes are available upon request from the
authors. Following polymerase chain reaction amplification, end
point fluorescence was read with the Applied Biosystems 7900HT
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sinstrument and genotypes were assigned using Allelic Discrimina-
tion Software (Applied Biosystems SDS Software v.1.7a). Quality
control (QC, 10%) samples were included and each analysis
included no DNA template controls. Laboratory personnel were
blinded to QC and case–control status. In all, 1697 women from
the NHS (524 colorectal adenoma cases and 517 matched controls
as well as 181 colorectal cancer cases and 475 matched controls)
were successfully genotyped, as well as 2275 men from the HPFS
(372 colorectal adenoma cases and 712 matched controls as well as
171 colorectal cancer cases and 347 matched controls) and from
the PHS (258 colorectal cancer cases and matched controls).
Statistical analyses
Adenoma risk was considered in relation to the CCND1 genotypes.
Cyclin D1 A870G was categorised into the three genotypes (G/G,
G/A, and A/A) and as noncarriers (i.e., the wild type, G/G) vs carriers
of the variant A allele (A/A, G/AþA/A). We conducted analyses
for all three cohorts separately and then combined analyses,
pooling data from the NHS, HPFS, and PHS, with adjustment
for age, gender, and body mass index (BMI). For analysis of the
main effect of genotype, logistic regression was used to compute
odds ratio (OR) and 95% confidence intervals (CIs), control for a
variety of potentially confounding variables, and to test for gene–
environment interactions. Although the data sets were initially
based on matched cases and controls, the stratified analyses
required unconditional analysis. Moreover, conditional logistic
regression yielded similar results as obtained when running
unconditional logistic regression models, thus we report OR)
derived from unconditional regression models throughout the
manuscript. Specifically, analyses involving NHS, HPFS, and PHS
cancer cases and controls were controlled for age, family history of
colorectal cancer (NHS and HPFS only), smoking history, aspirin
use, BMI, postmenopausal status and postmenopausal hormone
(PMH) use (NHS only), physical activity, and intake of red meat,
folic acid and alcohol, and history of previous endoscopy (HPFS
only). For colorectal adenoma, separate analyses for men and
women using unconditional logistic regression were controlled for
age, history of previous endoscopy, year of endoscopy, family
history of colorectal cancer, smoking history, aspirin use, BMI,
PMH use among postmenopausal women (NHS only), physical
activity, and intake of red meat, charred meat, folate, and alcohol.
In subanalyses, men and women in the adenoma groups were
combined for gene–environment interactions and were controlled
for age, sex, and family history of colorectal cancer. Analyses
involving PHS cancer cases and controls were controlled for age,
smoking status, aspirin use, BMI, physical activity, and intake of
red meat, vitamins, and alcohol.
The effects of various dietary and lifestyle exposures on colon
cancer and adenoma risk were tested in conjunction with CCND1
genotype. In the NHS colorectal cancer group, CCND1 genotypes
were analysed in combination with micrograms (mg) per day of
folate including supplements (p310, 4310), milligrams (mg) per
day of vitamin B6 pyridoxine (p2.5, 42.5) and grams (g) per day
of methionine (p1.84, 41.84), based on median distributions in
the control population, regular aspirin intake (yes, no), family
history of colorectal cancer (yes, no), pack-years of smoking before
age 30 (0, p10, 410), g per day of alcohol (o30, X30), age at
diagnosis (p65, 465), and PMH use among postmenopausal
women (never/past, current). In subanalyses, we stratified on the
stage of disease (stage I (muscle only) vs stages II and III combined
(pericolic or perirectal tissue, with or without involvement of
lymph nodes)) and site (colon vs rectum). In the NHS adenoma
group, CCND1 genotypes were analysed in combination with mg
per day of folate including supplements (p310, 4310), mg per day
of vitamin B6 (pyridoxine), and g per day of methionine (p1.84,
41.84), based on median distributions in the control population,
family history of colorectal cancer (yes, no) both alone and in
conjunction with adenoma size (small/large), pack-years of
smoking (0 years, o25 years, X25 years), g per day of alcohol
(o30, X30), age at diagnosis (p60, 460), regular aspirin intake
(yes, no), PMH use among postmenopausal women (never/past,
current), site (proximal vs distal), and size (large vs small) of
adenoma. In the HPFS adenoma group, CCND1 genotypes were
analysed in combination with mg per day of folate including
supplements (p338, 339–496, X497), and g per day of methionine
(p2.15, 42.15), based on median distributions in the control
population, regular aspirin intake (yes, no), age at diagnosis (p60,
460), pack-years of smoking (0 years, o25 years, X25 years), g
per day of alcohol (o5, 5–30, 430), and family history of
colorectal cancer (yes, no). In subanalyses, we stratified on age at
diagnosis (p60, 460) and site (proximal vs distal), and size (large
vs small) of adenoma. In the HPFS cancer group, CCND1 genotypes
were analysed in combination with mg per day of folate including
supplements (p338, 339–496, X497), and g per day of methionine
(p2.15, 42.15), based on median distributions in the control
population, regular aspirin intake (yes, no), age at diagnosis (p60,
460), pack-years of smoking (0 years, o25 years, X25 years), g
per day of alcohol (o5, 5–30, 430), and family history of
colorectal cancer (yes, no). In subanalyses, we stratified on the
stage of disease (advanced vs not) and site (colon vs rectum). In
the PHS colorectal cancer group, CCND1 genotypes were analysed
in combination with smoking (never, past, current), vitamin intake
(never, past, current), aspirin assignment (yes, no), age at
diagnosis (p55, 455), site (rectum vs colon), alcohol intake
in drinks per day (1, X1), and age (p55, 455). Exposure
information for the NHS was updated from 1990, 1992, 1994, 1996
to 1998. Exposure information for the HPFS and PHS was collected
at baseline in 1986 and 1982, respectively.
Statistical tests for interaction was based on the Wald test for
the crossproduct term in a model containing the main effects
of genotype and exposure variable as continuous variables. All
P-values are two-sided. All statistical analyses were carried out
using the SAS 8.2 statistical package (SAS Institute, Cary, NC, USA).
RESULTS
Dietary and lifestyle factors
A recent case–control study (Tranah et al, 2005) examined
whether the risk factors for colorectal adenoma and cancer were
similar in the cases and controls that provided blood samples
compared to previous observations for each cohort. For all
cohorts, the risk patterns observed for adenoma and cancer cases
in this sample were largely similar to those reported for the
entire cohort, as reported previously (Giovannucci et al, 1993;
Giovannucci et al, 2003, 1994a,b). Only for the PHS-nested case–
control study, the risk factors analysed were not associated with an
increased risk of colorectal cancer.
CCND1 polymorphism
The CCND1 A allele frequency ranged from 53 to 56% in the NHS,
HPFS, and PHS control populations and the genotype distributions
were in Hardy–Weinberg equilibrium. The A allele frequency was
slightly more frequent in our populations than in similar, white
populations of previous reports (42–43%) (Bala and Peltomaki,
2001; Le Marchand et al, 2003; Lewis et al, 2003).
In all cohorts combined, the CCND1 polymorphism did not
show statistically significant associations to risk of colorectal
cancer (odds ratio (OR), 1.04; 95% CI, 0.82–1.32) or adenoma (OR,
0.96; 95% CI, 0.77–1.18). Moreover, the risk associated with the
homozygous AA genotype did not appear to differ materially from
the heterozygous GA genotype (Table 1). The CCND1 A870G
polymorphism appeared to confer a modest, although statistically
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(OR, 1.59; 95% CI, 0.98–2.57). In contrast, the variant genotype
was not associated with risk of cancer or adenoma in men or risk
of adenoma in women. In addition, CCND1 genotype did not
confer a significant elevation in the risk for either large (X1cm) vs
small (o1cm) adenoma in either cohort (data not shown).
We assessed whether the influence of CCND1 genotype varied
for proximal as compared to distal colorectal cancers. The CCND1
A870G polymorphism appeared to confer an elevated risk for
cancers in the distal colon or rectum (rectum to splenic flexure)
(OR, 2.84; 95% CI, 1.27–6.33), but not for proximal cancers
(splenic flexure to caecum) (OR, 1.26; 95% CI, 0.61–2.60) in the
women. In contrast, among men in the HPFS, we found similar
risks for both proximal (OR, 1.09; 95% CI, 0.54–2.19) and distal
cancers (OR, 0.67; 95% CI, 0.37–1.21). Data on cancer location
within the bowel were not available from the PHS cohort. Previous
studies reported a younger age of onset for colorectal cancer
for subjects with HNPCC who possessed the AA or GA CCND1
genotype or the presence of the variant truncated CCND1
transcript (preferentially encoded by the A870G genotype) (Kong
et al, 2000; Bala and Peltomaki, 2001). We therefore examined
whether CCND1 genotype modified the influence of a common
family history of colorectal cancer (i.e., a history in one or
more first-degree relatives) on cancer and adenoma risk (Table 2).
Among female participants with the GG genotype, a family history
of colorectal cancer in one or more first-degree relatives was not
associated with a statistically significant elevation in colorectal
cancer risk. In contrast, for participants with the GA or AA
genotype, a family history was associated with a statistically
significant risk of colorectal cancer (multivariate OR, 1.95, 95% CI,
1.13–3.34). After adjusting for other covariates, the influence
of genotype on the relation between family history and cancer
risk was at the border of statistical significance (P for inter-
action¼0.06). However, in this cohort of women, we found no
material interaction between genotype, family history and
adenoma risk.
Similarly, among those with a family history, there was an
increased risk from the GA or AA genotype, compared to those
with the wild type. Among men in the HPFS, the influence of
CCND1 genotype on the relation between family history and
adenoma risk in the HPFS was statistically significant (P for
interaction¼0.02). Whereas family history conferred no signifi-
cant influence on adenoma risk among men with the GG genotype,
family history was associated with a significantly increased
adenoma risk (multivariate OR, 2.28, 95% CI, 1.32–3.95) among
men with the GA or AA genotypes. Nonetheless, among men in the
HPFS, we found no significant interaction between genotype,
family history, and colorectal cancer risk (data on family history
were not available from the PHS cohort). In addition, we examined
whether age at onset of disease influenced the overall association
between the genotype and colorectal cancer or adenomas. In these
analyses, we observed a higher risk of colorectal cancer among
women who carried one or two copies of the A allele and who had
a diagnosis of colorectal cancer at a later age (i.e., at or above age
65 years, as opposed to before age 65 years; AAþAG allele; RR,
2.33; 95% CI, 1.02–5.28). Similar risk increases were not observed
for colorectal adenomas among women, or among men.
We also assessed the associations of several dietary and lifestyle
factors with risk of colorectal cancer or adenoma stratified by
CCND1 genotype. In analyses of both cancer and adenoma, the
influence of BMI, smoking, aspirin use, and intakes of folate, red
meat, and alcohol did not differ significantly according to CCND1
genotype (in the PHS, folate intake was not assessed). However,
among postmenopausal women, the inverse relation between
postmenopausal oestrogen use and colorectal cancer and adenoma
risk appeared to be limited to the A870G polymorphism (Table 3).
Among women with the GG genotype, current PMH use did not
significantly influence the risk of colorectal cancer or adenoma.
However, among women with the GA or AA genotype, current
postmenopausal oestrogen use was associated with a significant
reduction in the risk of colorectal cancer when compared to never
or former users (multivariate OR, 0.57, 95% CI, 0.35–0.92),
although a test for statistical interaction was not significant.
Table 1 Associations between CCND1 A870G genotype and colorectal
carcinoma and adenoma risk in the NHS, HPFS, and PHS
CCND1 G to A Cases (%) Controls (%) OR (95% CI)
Cancer overall
N 610 1237
GG 125 (20.5) 264 (21.3) 1.0
a
AG 311 (51) 593 (48) 1.03 (0.78–1.36)
AA 174 (28.5) 380 (30.7) 1.12 (0.90–1.41)
AA+AG 485 (79.5) 973 (78.7) 1.04 (0.82–1.32)
P for trend 0.64
Adenoma overall
N 896 1229
GG 187 (20.9) 241 (19.6) 1.0
a
AG 441 (49.2) 614 (50) 0.95 (0.77–1.18)
AA 268 (29.9) 374 (30.4) 1.00 (0.78–1.28)
AA+AG 709 (79.1) 988 (80.4) 0.96 (0.79–1.18)
P for trend 0.99
NHS cancer
b
N 181 475
GG 29 (16) 110 (23.2) 1.0
a
AG 95 (52.5) 224 (47.2) 1.61 (0.96–2.68)
AA 57 (31.5) 141 (29.7) 1.55 (0.90–2.69)
AA+AG 152 (84) 365 (76.8) 1.59 (0.98–2.57)
P for trend 0.16
NHS adenoma
c
N 524 517
GG 108 (20.6) 100 (19.3) 1.0
a
AG 265 (50.6) 266 (51.5) 0.95 (0.67–1.33)
AA 151 (28.8) 151 (29.2) 0.92 (0.63–1.34)
AA+AG 416 (79.4) 417 (80.7) 0.94 (0.68–1.29)
P for trend 0.66
PHS cancer
c
N 258 415
GG 56 (21.7) 85 (20.5) 1.0
a
AG 136 (52.7) 203 (48.9) 1.02 (0.68–1.55)
AA 66 (25.6) 127 (30.6) 0.80 (0.51–1.27)
AA+AG 202 (78.3) 330 (79.5) 0.94 (0.64–1.39)
HPFS cancer
b
N 171 347
GG 40 (23.4) 69 (19.9) 1.0
a
AG 80 (46.8) 166 (47.8) 0.86 (0.53–1.40)
AA 51 (29.8) 112 (32.3) 0.81 (0.48–1.38)
AA+AG 131 (76.6) 278 (80.1) 0.84 (0.53–1.33)
P for trend 0.45
HPFS adenoma
c
N 372 712
GG 79 (21.2) 141 (19.8) 1.0
a
AG 176 (47.3) 348 (48.9) 0.96 (0.68–1.36)
AA 117 (31.5) 223 (31.3) 0.91 (0.63–1.33)
AA+AG 293 (78.8) 571 (80.2) 0.94 (0.68–1.31)
P for trend 0.61
CCND1¼cyclin D1; CI¼confidence interval; HPFS¼Health Professionals’ Follow-
Up Study; NHS¼Nurses’ Health Study; OR¼odds ratio; PHS¼Physicians’ Health
Study.
aReference group.
bUnconditional logistic regression adjusted for age, family
history of colorectal cancer, smoking history, aspirin use, BMI, PMH use, physical
activity, and intake of red meat, charred meat, folate, and alcohol.
cUnconditional
logistic regression adjusted for age, previous endoscopy, year of endoscopy, family
history of colorectal cancer, pack-years smoking, aspirin use, BMI, PMH use (NHS
only), physical activity, and intake of red meat, charred meat, folate, and alcohol.
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postmenopausal oestrogen use was associated with a significant
reduction in adenoma risk when compared to never or former
users (multivariate OR, 0.63, 95% CI, 0.45–0.87), although the test
for interaction was not significant.
DISCUSSION
In the present study, the GA or AA CCND1 genotype was
associated with a borderline significant increase in the risk of
colorectal cancer only among women. In contrast, we found no
association between CCND1 genotype and the risk of distal
colorectal adenoma in either women or men. Notably, among
postmenopausal women in the NHS, a reduced risk of colorectal
cancer or adenoma associated with current oestrogen use was
restricted to women with the GA or AA CCND1 genotype.
Postmenopausal oestrogen conferred no benefit among women
with GG genotype.
Our findings for colorectal cancer among women are consistent
with those of Le Marchand et al and others, which found a similar
increase in the risk of colorectal cancer among participants with
the GA or AA genotype (Kong et al, 2000; Porter et al, 2002; Le
Marchand et al, 2003). In contrast to a previous study of colorectal
adenoma (Lewis et al, 2003), we did not find an association
between CCND1 genotype and the risk of adenoma, although our
analysis was limited to adenoma of the distal colon and rectum.
Previous studies suggest that the GA or AA genotype is
associated with a younger age of onset for HNPCC. One of these
studies found that patients with HNPCC who carried the GA or AA
genotype developed colorectal cancer on average 11 years earlier
than those with the wild type (Kong et al, 2000). However, we are
unaware of any studies that have examined the interaction with a
sporadic (nonsyndromic) family history. In our study, the
presence of at least one A allele substantially augmented the effect
of a family history of colorectal cancer on the risk of colorectal
cancer in the NHS and the risk of colorectal adenoma in the HPFS.
However, we did not find similar interactions for colorectal
adenoma in the NHS and colorectal cancer in the HPFS. Given that
there was some residual risk for colorectal neoplasia among
individuals with the GG group, it appears unlikely that the G-to-A
polymorphism is one of the main components and main under-
lying mechanisms for some nonsyndromic cases of familial
colorectal cancer.
Numerous studies observed a significant reduction in the risk
of colorectal cancer and adenoma among PMH users (Serrano
et al, 2004), including a previous analysis of our female cohort
(Grodstein et al, 1998) and a large randomised trial of post-
menopausal women (Chlebowski et al, 2004). Nonetheless, no
study, to date, has examined whether CCND1 genotype modifies
the influence of PMH use on colorectal cancer and adenoma risk.
We found that the benefit associated with PMH use was restricted
to those with GA or AA genotype. In the Shanghai Women’s Breast
Cancer Study, the increased risk of breast cancer associated with
oestrogens was limited to women with the GA or AA genotype
(OR¼2.6) (Shu et al, 2005). In contrast, women with the GG
genotype experienced no increased risk for breast cancer in
association with PMH use (OR¼0.8). In a second study, oral
contraceptive use was associated with an increased risk of breast
cancers with CCND1 overexpression, but was unrelated to those
without CCND1 overexpression (Terry et al, 2002). These data
suggest that the CCND1 GA or AA genotype may augment the
various influences of oestrogen in decreasing the risk of colorectal
cancer and adenoma as well as increasing the risk of breast cancer.
In previous studies, CCND1 can bind directly to the oestrogen
receptor, transactivate oestrogen response elements (Zhou et al,
2001), and regulate oestrogen-dependent enhancer activity
(Zafonte et al, 2000).
The strengths of our study include its relatively large size,
prospective design, detailed data on potential confounders,
and high follow-up rate. In particular, we had a unique ability
to examine a wide range of exposures and interaction with
genotype. As participants were health professionals, the accuracy
of self-reported data is likely to be high; information on many
Table 2 Relationship between family history of colorectal cancer and risk
of colorectal cancer and adenoma among postmenopausal women in the
NHS and men in the HPFS, stratified by CCND1 A870G genotype
Family history of colorectal cancer
No Yes
Case/
control
OR
(reference)
Case/
control OR (95% CI)
P for
interaction
NHS cancer
a* 0.06
GG 22/89 1.0 7/21 1.15 (0.38–3.50)
GA/AA 113/316 1.0 31/45 1.95 (1.13–3.34)
NHS adenoma
b 0.77
GG 75/76 1.0 33/24 1.77 (0.84–3.72)
GA/AA 295/338 1.0 121/79 1.85 (1.31–2.61)
HPFS cancer
a 0.80
GG 27/59 1.0 13/10 3.15 (1.14–8.67)
GA/AA 107/241 1.0 24/37 1.44 (0.80–2.57)
HPFS adenoma
b 0.02
GG 74/126 1.0 5/15 0.52 (0.17–1.60)
GA/AA 262/543 1.0 31/28 2.28 (1.32–3.95)
CCND1¼cyclin D1; CI¼confidence interval; HPFS¼Health Professionals’ Follow-
Up Study; NHS¼Nurses’ Health Study; OR¼odds ratio. *Case and control
numbers differ from total because of missing information on family history.
aUnconditional logistic regression adjusted for age, PMH use (NHS only), smoking
history, aspirin use, BMI, physical activity, and intake of red meat, charred meat, folate,
and alcohol.
bUnconditional logistic regression adjusted for age, history of previous
endoscopy, year of endoscopy, PMH use, aspirin use, BMI, physical activity, and intake
of red meat, well-done meat, folic acid, alcohol, total calories, and caloric-adjusted
total fat.
Table 3 Relationship between PMH use and risk of colorectal cancer
and adenoma among postmenopausal women in the NHS stratified by
CCND1 A870G genotype
Postmenopausal hormone use
Never–past use Current use
Case/
control
OR
(reference)
Case/
control OR (95% CI)
P for
interaction
NHS cancer
a 0.37
GG 14/69 1.0 13/30 2.34 (0.75–7.31)
GA/AA 95/181 1.0 38/135 0.57 (0.35–0.92)
NHS adenoma
b 0.33
GG 56/50 1.0 36/34 1.21 (0.55–2.64)
GA/AA 209/166 1.0 150/189 0.63 (0.45–0.87)
CCND1¼cyclin D1; CI¼confidence interval; NHS¼Nurses’ Health Study;
OR¼odds ratio; PMH¼postmenopausal hormone.
aUnconditional logistic regres-
sion adjusted for age, family history of colorectal cancer, smoking history, aspirin use,
BMI, physical activity, and intake of red meat, charred meat, folate, and alcohol.
bUnconditional logistic regression adjusted for age, history of previous endoscopy,
year of endoscopy, family history of colorectal cancer, aspirin use, BMI, physical
activity, and intake of red meat, well-done meat, folic acid, alcohol, total calories, and
caloric-adjusted total fat.
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(Willett et al, 1985; Rimm et al, 1990; Wolf et al, 1994). Moreover,
because our study was nested within three larger, well-defined
cohorts, control participants were sampled from the same
population as case participants. Thus, our results are unlikely to
be influenced by population stratification or selection bias.
Another strength of our study is that we were able to look at
both cancer and adenoma as end points. Moreover, our cancer
cases were incident cases, which may be important if cyclin D
affects survival, as suggested by Le Marchand et al (2003); a study
which collected DNA after diagnosis may not be able to include
fatal cancers.
Our study has several limitations. Firstly, we did not specify on
our questionnaire, whether study participants underwent a
colonoscopy or sigmoidoscopy. Thus, with regard to our analysis
of adenoma, it is possible that some controls were not entirely free
of proximal adenomatous polyps (that were beyond the reach of
the flexible sigmoidoscope), thus potentially limiting the generali-
sability of our adenoma findings. Moreover, since we limited our
analysis to adenoma within the reach of the flexible sigmoido-
scope, we were unable to assess the association of genotype with
the risk of proximal adenoma. However, for the analysis of
colorectal cancer in our cohort of women, the risk associated with
A870G genotype was, in fact, greater for cancers of the distal colon
and rectum than for more proximal lesions. Finally, even though
our study is of fairly large size, it may still have been
underpowered for certain gene–environment interactions.
In summary, our results suggest that the risk of both colorectal
cancer and adenoma associated with a family history of colorectal
cancer may be augmented by the CCND1 A870G genotype.
Moreover, the A870G genotype appears to enhance the protective
effect of postmenopausal oestrogen use on the development of
colorectal neoplasia. Additional studies are warranted to confirm
this potential interaction between CCND1 genotype and post-
menopausal oestrogen use.
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